Phase 2 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women aged 18 or older
- Women who are pre-menopausal or peri-menopausal, meaning they have had a period within the 12 months before or after their breast cancer diagnosis, or whose hormone test results show they are not yet post-menopausal
- People who are planning to take a hormone-suppressing injection (GnRHa) together with a hormone-blocking tablet (tamoxifen, anastrozole, exemestane, or letrozole) to treat stage 1–3 breast cancer or breast cancer that has spread to other parts of the body
- People who have previously used hormone-suppressing injections for reasons unrelated to cancer, or during chemotherapy
- People who are not planning to have both ovaries and fallopian tubes surgically removed during the 6-month study period
- People who have finished chemotherapy if it was part of their treatment (certain other ongoing treatments, such as trastuzumab, pertuzumab, bone-strengthening medication, or some targeted cancer therapies, are permitted at the same time)
- People who are able to understand and sign a consent form agreeing to take part in the study
Who may not be able to join:
- People who have already had both ovaries and fallopian tubes surgically removed
- People who are pregnant or breastfeeding (a pregnancy test will be checked before the study begins)
- People who are currently using estrogen products applied to the skin or taken throughout the body
- People with a known allergy or sensitivity to the medications goserelin or leuprolide, or to any of the ingredients in those medications
- People who are unable to swallow or take tablets by mouth
- People who have a medical condition that would affect how their body absorbs hormone-blocking tablets (confirm with trial site)
- People who have had, or currently have, another type of cancer where the cancer itself or its treatment could affect how safely or accurately this trial can be assessed, in the opinion of the treating doctor
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Norah L Henry, University of Michigan Rogel Cancer Center
Phone: 1-800-865-1125
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of participants with ultrasensitive estradiol concentration > 10 pg/ml
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.